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With respect to the potential impact of LGE-based risk stratification for VA, the most obvious application is identification of optimal candidates for ICDs for primary prevention of sudden cardiac arrest.
Although the strong association between LGE findings and VA risk is clear, application of these results in clinical practice for ICD risk stratification is much less straightforward because of the heterogeneity of these studies. In addition to the different endpoints used, ICD indications varied among the studies, and cardiac resynchronization defibrillators were sometimes implanted. Furthermore, the patients enrolled ranged from those with severe LV dysfunction to those with only mild LV dysfunction, and some patients in these studies did not even meet criteria for ICD implantation. Even so, the consistently strong associations across studies between LGE and VA risk suggest that LGE may have significant utility for this purpose in the future.
The potential impact of LGE for risk stratification in ischemic cardiomyopathy (ICM) is highlighted by the fact that nearly two-thirds of the patients in the National Cardiovascular Data Registry (NCDR) ICD Registry (version 1) had ischemic heart disease, and more than one-half of those patients had prior myocardial infarction (2) . One challenge with respect to using
LGE for risk stratification in ICM patients is that it is not practical to use absence of LGE to identify a low- Several studies in the current meta-analysis (1) showed that the gray zone was strongly associated with VA risk. The threshold level used to identify a high-risk LGE pattern in gray zone mass in ICM patients was 16.7 g (median value) in one meta-analysis study, while another meta-analysis study in a mixed ICM/NICM cohort with cardiac resynchronization therapy defibrillators found that a gray zone mass of <9.5 g combined with a total scar volume less than 16% of the LV volume identified patients at very low risk for appropriate ICD therapies. A ratio of gray zone mass to core infarct mass <0.6 also identified low-risk patients in another study of patients with standard
ICDs. In addition, one of the NICM studies found that a threshold value of 6.1% for overall scar volume conveyed an increased risk of major adverse cardiac (Figure 1 ). These clinical studies should also evaluate whether LGE adds to risk scores (7, 8) and other risk stratification tools that we already have.
Furthermore, we need to acknowledge that not all patients will be able to receive CMR with gadolinium because of chronic kidney disease or contraindications to CMR.
In summary, the current research supports a strong association between LGE findings on CMR and subsequent VA in the setting of LV dysfunction, and the scar gray zone appears to be at least as important as total scar volume for risk stratification. In fact, all the studies in the meta-analysis showed that LGE findings conveyed increased risk for VA, and LGE findings were often still associated with VA risk after adjustment for other factors. Consequently, the findings from this meta-analysis (1) indicate that the "fault" in heart failure patients with respect to VA really does lie in the extent and characteristics of their myocardial scars and that randomized clinical trials are needed to determine whether LGE can determine which patients are most likely to benefit from clinical interventions designed to decrease morbidity and mortality from VA.
